Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice
Open Access
- 11 February 2024
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (12) , e2304238
Abstract
There is no curative treatment for chronic auto‐inflammatory diseases including rheumatoid arthritis, and current treatments can induce off‐target side effects due to systemic immune suppression. This work has previously shown that dexamethasone‐pulsed tolerogenic dendritic cells loaded with the arthritis‐specific antigen human proteoglycan can suppress arthritis development in a proteoglycan‐induced arthritis mouse model. To circumvent ex vivo dendritic cell culture, and enhance antigen‐specific effects, drug delivery vehicles, such as liposomes, provide an interesting approach. Here, this work uses anionic 1,2‐distearoyl‐sn‐glycero‐3‐phosphoglycerol liposomes with enhanced loading of human proteoglycan‐dexamethasone conjugates by cationic lysine tetramer addition. Antigen‐pulsed tolerogenic dendritic cells induced by liposomal dexamethasone in vitro enhanced antigen‐specific regulatory T cells to a similar extent as dexamethasone‐induced tolerogenic dendritic cells. In an inflammatory adoptive transfer model, mice injected with antigen‐dexamethasone liposomes have significantly higher antigen‐specific type 1 regulatory T cells than mice injected with antigen only. The liposomes significantly inhibit the progression of arthritis compared to controls in preventative and therapeutic proteoglycan‐induced arthritis mouse models. This coincides with systemic tolerance induction and an increase in IL10 expression in the paws of mice. In conclusion, a single administration of autoantigen and dexamethasone‐loaded liposomes seems to be a promising antigen‐specific treatment strategy for arthritis in mice.Keywords
Funding Information
- ReumaNederland
This publication has 64 references indexed in Scilit:
- Design of liposomes as drug delivery system for therapeutic applicationsInternational Journal of Pharmaceutics, 2021
- The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic reviewRheumatology International, 2020
- Targeted and triple therapy-based liposomes for enhanced treatment of rheumatoid arthritisInternational Journal of Pharmaceutics, 2020
- Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future DirectionsDrugs, 2016
- Foxp3+ regulatory T cells are activated in spite of B7‐CD28 and CD40‐CD40L blockadeEuropean Journal of Immunology, 2013
- Enhanced GITR/GITRL interactions augment IL‐27 expression and induce IL‐10‐producing Tr‐1 like cellsEuropean Journal of Immunology, 2012
- Designing micro- and nano-particles for treating rheumatoid arthritisArchives of Pharmacal Research, 2011
- Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasoneInternational Journal of Pharmaceutics, 2010
- Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptorsClinical Immunology, 2006
- Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotypeArthritis & Rheumatism, 2004